Albuminuria
Recent clinical, regulatory, research and industry developments relating to this disease.
Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026ACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous Aetiology
- Q1 2027Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes
- Q2 2027Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical Trial
- Q4 2029Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Clinical MilestonesViewHide
- 2026-06-30Effect of Montelukast on Kidney and Vascular Function in Type 1 DiabetesResults expected Q1 2027
- 2026-05-19Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, EmpagliflozinResults expected Q4 2029
- 2026-04-27Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical TrialResults expected Q2 2027
- 2025-09-23ACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous AetiologyResults expected Q3 2026
- 2026-06-30ClinicalEffect of Montelukast on Kidney and Vascular Function in Type 1 DiabetesResults expected Q1 2027
- 2026-05-19ClinicalTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, EmpagliflozinResults expected Q4 2029
- 2026-04-27ClinicalEfficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical TrialResults expected Q2 2027
- 2025-09-24ClinicalOptimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.Completed
- 2025-09-23ClinicalACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous AetiologyResults expected Q3 2026
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) asso… (2022)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cardiovascular Diseases2
- Renal Insufficiency, Chronic2
- Diabetes Mellitus1
- Diabetes Mellitus, Type 21
- Diabetic Nephropathies1
- Diabetic Retinopathy1
- Kidney Diseases1
- Oxidative Stress1
Leading journals6
- Circulation1
- Clinical chemistry1
- Diabetologia1
- International journal of molecular sciences1
- Journal of the American Heart Association1
- The New England journal of medicine1
Leading researchers8
- Agarwal R1
- Arnold M1
- Arnott C1
- Bakris G1
- Bakris GL1
- Barzilay JI1
- Brown-Frandsen K1
- Bruns DE1
Affiliations (unnormalised)6
- AHEPA Hospital1
- Brigham and Women's Hospital1
- Department of Clinical Pharmacy and Pharmacology1
- Department of Laboratory Medicine1
- Diabetes Research Centre1
- From KfH Kidney Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Albuminuria is the presence of albumin in the urine. It is used as an indicator of kidney disease and kidney damage, and it is also recognized as a biomarker of chronic kidney disease progression.
The supplied material does not identify a single cause of albuminuria itself. It is described as a manifestation of kidney disease, and in chronic kidney disease it is linked to podocyte damage and proteinuria.
Albuminuria reflects increased urinary albumin excretion due to kidney damage, particularly glomerular injury. The grounding links it to podocyte damage, oxidative stress, inflammation, and vascular dysfunction in chronic kidney disease, with associated proteinuria and renal fibrosis.
Albuminuria is associated with diabetes mellitus and chronic kidney disease. It is also linked to systemic vascular disease and cardiovascular disease, including coronary artery disease, stroke, heart failure, arrhythmias, and microvascular disease.
The grounding supports laboratory screening and surveillance for albuminuria in the diagnosis and management of diabetes mellitus and in chronic kidney disease monitoring. It also supports treatment with albuminuria-lowering therapeutic agents, including glucose-lowering therapies such as GLP-1 receptor agonists and DPP-4 inhibitors, as part of broader management of kidney and cardiovascular risk.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.